Lantheus Holdings, Inc. $LNTH Position Cut by TD Asset Management Inc

TD Asset Management Inc trimmed its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 10.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 711,894 shares of the medical equipment provider’s stock after selling 79,056 shares during the quarter. TD Asset Management Inc owned about 1.07% of Lantheus worth $47,377,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Osterweis Capital Management Inc. bought a new position in Lantheus in the 2nd quarter worth approximately $36,000. Hantz Financial Services Inc. boosted its stake in Lantheus by 412.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 396 shares in the last quarter. Larson Financial Group LLC boosted its stake in Lantheus by 324.5% during the 4th quarter. Larson Financial Group LLC now owns 658 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 503 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in Lantheus by 71.4% during the 4th quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 275 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in Lantheus by 30.3% during the 4th quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock valued at $66,000 after purchasing an additional 230 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on LNTH shares. Citizens Jmp increased their price target on Lantheus from $85.00 to $115.00 and gave the company a “market outperform” rating in a research note on Friday, May 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lantheus in a research note on Tuesday, May 26th. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. Wall Street Zen lowered Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, JonesTrading lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and a consensus target price of $101.86.

Lantheus Stock Down 1.8%

Shares of Lantheus stock opened at $100.98 on Friday. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $104.00. The firm has a market capitalization of $6.57 billion, a PE ratio of 24.33 and a beta of -0.03. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. The stock’s fifty day moving average is $88.01 and its 200-day moving average is $74.96.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, beating the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. During the same period in the prior year, the business posted $1.53 earnings per share. Lantheus’s revenue was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities analysts anticipate that Lantheus Holdings, Inc. will post 4.42 earnings per share for the current year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.